Dieter Vandenheuvel

Dieter Vandenheuvel

Auto-generated profile, based on publicly available information

Dieter Vandenheuvel

Laboratory of Gene Technology, KU Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
GBGéraldine Broeckx
Géraldine Broeckx
DVDieter Vandenheuvel
Dieter Vandenheuvel
ICIngmar J.J. Claes
Ingmar J.J. Claes
SLSarah Lebeer
Sarah Lebeer
FKFilip Kiekens
Filip Kiekens

7 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EAEvelien Adriaenssens
Evelien Adriaenssens
JVJohan Van Vaerenbergh
Johan Van Vaerenbergh
DVDieter Vandenheuvel
Dieter Vandenheuvel
VDVincent Dunon
Vincent Dunon
Pieter-Jan CeyssensPieter-Jan Ceyssens
Pieter-Jan Ceyssens
Rob LavigneRob Lavigne
Rob Lavigne
The bacterium ‘Dickeya solani’, an aggressive biovar 3 variant of Dickeya dianthicola, causes rotting and blackleg in potato. To control this pathogen using bacteriophage therapy, we isolated and characterized two closely related and specific bacteriophages, vB_DsoM_LIMEstone1 and vB_DsoM_LIMEstone2. The LIMEstone phages have a T4-related genome organization and share DNA similarity with Salmonella phage ViI. Microbiological and molecular characterization of the phages deemed them suitable and promising for use in phage therapy. The phages reduced disease incidence and severity on potato tubers in laboratory assays. In addition, in a field trial of potato tubers, when infected with ‘Dickeya solani’, the experimental phage treatment resulted in a higher yield. These results form the basis for the development of a bacteriophage-based biocontrol of potato plants and tubers as an alternative for the use of antibiotics.

15 May 2015 in Applied and Environmental Microbiology
Verified
Journal Article
Open access
PDF file
DGDiana Gutiérrez
Diana Gutiérrez
DVDieter Vandenheuvel
Dieter Vandenheuvel
BMBeatriz Martínez
Beatriz Martínez
ARAna Rodríguez
Ana Rodríguez
Rob LavigneRob Lavigne
Rob Lavigne
Pilar GarcíaPilar García
Pilar García
Phage therapy is a promising option for fighting against staphylococcal infections. Two lytic phages, vB_SauM_phiIPLA-RODI (phiIPLA-RODI) and vB_SepM_phiIPLA-C1C (phiIPLA-C1C), belonging to the Myoviridae family and exhibiting wide host ranges, were characterized in this study. The complete genome sequences comprised 142,348 bp and 140,961 bp and contained 213 and 203 open reading frames, respectively. The gene organization was typical of Spounavirinae members, with long direct terminal repeats (LTRs), genes grouped into modules not clearly separated from each other, and several group I introns. In addition, four genes encoding tRNAs were identified in phiIPLA-RODI. Comparative DNA sequence analysis showed high similarities with two phages, GH15 and 676Z, belonging to the Twort-like virus genus (nucleotide identities of >84%); for phiIPLA-C1C, a high similarity with phage phiIBB-SEP1 was observed (identity of 80%). Challenge assays of phages phiIPLA-RODI and phiIPLA-C1C against planktonic staphylococcal cells confirmed their lytic ability, as they were able to remove 5 log units in 8 h. Exposure of biofilms to phages phiIPLA-RODI and phiIPLA-C1C reduced the amount of adhered bacteria to about 2 log units in both monospecies and dual-species biofilms, but phiIPLA-RODI turned out to be as effective as the mixture of both phages. Moreover, the frequencies of bacteriophage-insensitive mutants (BIMs) of Staphylococcus aureus and S. epidermidis with resistance to phiIPLA-RODI and phiIPLA-C1C were low, at 4.05 × 10 −7 ± 2.34 × 10 −9 and 1.1 × 10 −7 ± 2.08 × 10 −9 , respectively. Overall, a generally reduced fitness in the absence of phages was observed for BIMs, which showed a restored phage-sensitive phenotype in a few generations. These results confirm that lytic bacteriophages can be efficient biofilm-disrupting agents, supporting their potential as antimicrobials against staphylococcal infections.

9 November 2015 in Annual Review of Virology
Verified
Journal Article
Closed access
DVDieter Vandenheuvel
Dieter Vandenheuvel
Rob LavigneRob Lavigne
Rob Lavigne
HBHarald Brüssow
Harald Brüssow
Recently, a number of phage therapy phase I and II safety trials have been concluded, showing no notable safety concerns associated with the use of phage. Though hurdles for efficient treatment remain, these trials hold promise for future phase III clinical trials. Interestingly, most phage formulations used in these clinical trials are straightforward phage suspensions, and not much research has focused on the processing of phage cocktails in specific pharmaceutical dosage forms. Additional research on formulation strategies and the stability of phage-based drugs will be of key importance, especially with phage therapy advancing toward phase III clinical trials.

29 November 2017 in Frontiers in Microbiology
Verified
Journal Article
Open access
IBIlke De Boeck
Ilke De Boeck
SWStijn Wittouck
Stijn Wittouck
SWSander Wuyts
Sander Wuyts
EOEline F. M. Oerlemans
Eline F. M. Oerlemans
MBMarianne F. L. van Den Broek
Marianne F. L. van Den Broek
SLSarah Lebeer
Sarah Lebeer
To improve our understanding of upper respiratory tract (URT) diseases and the underlying microbial pathogenesis, a better characterization of the healthy URT microbiome is crucial. In this first large-scale study, we obtained more insight in the URT microbiome of healthy adults. Hereto, we collected paired nasal and nasopharyngeal swabs from 100 healthy participants in a citizen-science project. High-throughput 16S rRNA gene V4 amplicon sequencing was performed and samples were processed using the Divisive Amplicon Denoising Algorithm 2 (DADA2) algorithm. This allowed us to identify the bacterial richness and diversity of the samples in terms of amplicon sequence variants (ASVs), with special attention to intragenus variation. We found both niches to have a low overall species richness and uneven distribution. Moreover, based on hierarchical clustering, nasopharyngeal samples could be grouped into some bacterial community types at genus level, of which four were supported to some extent by prediction strength evaluation: one intermixed type with a higher bacterial diversity where Staphylococcus, Corynebacterium, and Dolosigranulum appeared main bacterial members in different relative abundances, and three types dominated by either Moraxella, Streptococcus, or Fusobacterium. Some of these bacterial community types such as Streptococcus and Fusobacterium were nasopharynx-specific and never occurred in the nose. No clear association between the nasopharyngeal bacterial profiles at genus level and the variables age, gender, blood type, season of sampling, or common respiratory allergies was found in this study population, except for smoking showing a positive association with Corynebacterium and Staphylococcus. Based on the fine-scale resolution of the ASVs, both known commensal and potential pathogenic bacteria were found within several genera – particularly in Streptococcus and Moraxella – in our healthy study population. Of interest, the nasopharynx hosted more potential pathogenic species than the nose. To our knowledge, this is the first large-scale study using the DADA2 algorithm to investigate the microbiota in the “healthy” adult nose and nasopharynx. These results contribute to a better understanding of the composition and diversity of the healthy microbiome in the URT and the differences between these important URT niches. Trial Registration: Ethical Committee of Antwerp University Hospital, B300201524257, registered 23 March 2015, ClinicalTrials.gov Identifier: NCT02 933983.

1 August 2013 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
DVDieter Vandenheuvel
Dieter Vandenheuvel
ASAbhishek Singh
Abhishek Singh
KVKatrien Vandersteegen
Katrien Vandersteegen
JKJochen Klumpp
Jochen Klumpp
Rob LavigneRob Lavigne
Rob Lavigne
GMGuy Van Den Mooter
Guy Van Den Mooter